Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis

Purpose Metastatic triple negative breast cancer (mTNBC) is associated with poor prognosis and limited treatment options. It is known to be high immunogenic, with a high level of programmed cell death-ligand 1 (PD-L1) expression. PD-L1 expression in TNBC does not have a clear prognostic relevance. I...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research and treatment 2022, Vol.191 (1), p.137-145
Main Authors: Bianco, Nadia, Milano, Monica, Pagan, Eleonora, Oriecuia, Chiara, Bagnardi, Vincenzo, Rocco, Elena Guerini, Santomauro, Giorgia Irene, Peruzzotti, Giulia, Colleoni, Marco, Viale, Giuseppe
Format: Article
Language:English
Subjects:
Analysis
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Apoptosis
B7-H1 Antigen
Breast cancer
Cancer
Cancer research
Care and treatment
Cell death
Chemotherapy
Epidemiology
Humans
Immune response
Immunogenicity
Immunotherapy
Medical prognosis
Medicine
Medicine & Public Health
Metastases
Metastasis
Oncology
Patient outcomes
Patients
PD-L1 protein
Prognosis
Retrospective Studies
Triple Negative Breast Neoplasms - drug therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Metastatic triple negative breast cancer (mTNBC) is associated with poor prognosis and limited treatment options. It is known to be high immunogenic, with a high level of programmed cell death-ligand 1 (PD-L1) expression. PD-L1 expression in TNBC does not have a clear prognostic relevance. In this study, we aimed to assess survival outcomes according to PD-L1 expression in the real world. Methods We retrospectively analyzed mTNBC patients treated with first-line chemotherapy at European Institute of Oncology with evaluable PD-L1 expression. Primary endpoints were Progression-Free Survival (PFS) and Overall Survival (OS) according to PD-L1 expression. Results From January 2000 to December 2018, 190 patients fulfilled the inclusion criteria for final analysis. PD-L1 positive (≥ 1%) subgroup showed a median PFS of 6.8 vs 5.6 months in PD-L1 negative subgroup (PFS-HR 1.25, 95% CI 0.89–1.74, p -value = 0.191), while at data cutoff we had 120 deaths in the PD-L1 
ISSN:0167-6806
1573-7217
DOI:10.1007/s10549-021-06407-0